Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

Is Rizatriptan recalled?

Yes — there is an active recall. 6 ongoing FDA recalls mention Rizatriptan (9 total). Check the affected lots below.

Most common reason: Nitrosamine impurity (6 of these recalls)

Recalls are matched by product description. A recall usually affects specific lots, not every package of Rizatriptan. “Active” means an FDA recall is still ongoing; “closed” means it was terminated or completed. Checked against openFDA on Oct 10, 2026.

Rizatriptan recalls on record

none so far in 2026; 9 on record, newest first
Class II · Moderate risk

Rizatriptan Benzoate Tablets

CGMP Deviations: detection of N-nitroso-dimethyl-rizatriptan impurity, above the FDA recommended acceptable intake limit.

Ongoing Nitrosamine impurity Ascend Laboratories, LLC NDC 67877-262-18 D-0534-2025
Class II · Moderate risk

Rizatriptan Benzoate Tablets

CGMP Deviations: detection of N-nitroso-dimethyl-rizatriptan impurity, above the FDA recommended acceptable intake limit.

Ongoing Nitrosamine impurity Ascend Laboratories, LLC NDC 67877-261-18 D-0533-2025
Class II · Moderate risk

Rizatriptan Benzoate Tablets USP

CGMP Deviations: N-Nitroso Desmethyl Rizatriptan Impurity results that are above the FDA acceptable limit.

Ongoing Nitrosamine impurity Glenmark Pharmaceuticals Inc., USA NDC 68462-466-99 D-0533-2024
Class II · Moderate risk

Rizatriptan Benzoate Tablets USP

CGMP Deviations: N-Nitroso Desmethyl Rizatriptan Impurity results that are above the FDA acceptable limit.

Ongoing Nitrosamine impurity Glenmark Pharmaceuticals Inc., USA NDC 68462-465-99 D-0532-2024